ΔCxxC mice showed myeloid-biased hematopoiesis and impaired lymphopoiesis. (A) Experimental design of the hematopoietic-specific deletion of Kdm2b exon 13. (B) PB cell counts in WT and ΔCxxC mice in noncompetitive BM transplantation settings as in panel A . PB cell counts in WT (n = 5) and ΔCxxC (n = 5) mice after the injection of tamoxifen (Tam) are shown as means ± standard deviation (SD). (C) Proportions of myeloid cells (Mac-1⁺ and/or Gr-1⁺), B cells (B220⁺), and T cells (CD4⁺ or CD8⁺) among CD45.2 donor-derived hematopoietic cells and their absolute numbers in PB from WT (n = 5) and ΔCxxC (n = 4) mice 4 weeks after the injection of tamoxifen. Data are shown as means ± SD. (D) BM analysis 4 weeks after the injection of tamoxifen. Absolute numbers of CD45.2 HSCs, LSK cells, LMPPs, myeloid progenitors, and CLPs from a unilateral femur and tibia pair in WT and ΔCxxC (n = 5). Data are shown as means ± SD. (E) Spleen and thymus weights 4 weeks after the injection of tamoxifen. Data are shown as means ± SD. *P < .05; **P < .01; ***P < .001 by Student t test. CMP, common myeloid progenitor; GMP, granulocyte/macrophage progenitor; Hb, hemoglobin; i.p., intraperitoneal; MEP, megakaryocyte/erythroid progenitor; ns, not significant; Plt, platelet; WBC, white blood cell.